Evidence map›Paper›PMID 36276363›Full record

SynthesisFrontiers in public health2022

A systematic review of the early dialogue frameworks used within health technology assessment and their actual adoption from HTA agencies.

Nora Ibargoyen-Roteta, Lorea Galnares-Cordero, Gaizka Benguria-Arrate, Kelly Rocío Chacón-Acevedo, María Paula Gutiérrez-Sepulveda, Eduardo Low-Padilla, Ilich Herbert De La Hoz-Siegler, Claudia Isabel Guevara-Pérez, Ángel Del Pozo-Pérez, Marta Suárez and 3 more

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Health Technology Assessment in the Early Phases of Development of Medical Devices: A Catalyst for Sustainable Growth and Innovation.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. How can managed entry agreements contribute to coverage decisions in Latin America?International journal of technology assessment in health care · 2024
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nora Ibargoyen-RotetaBasque Office for HTA (Osteba)/Basque Foundation for Health Innovation and Research (BIOEF), Barakaldo, Spain.
Lorea Galnares-CorderoBasque Office for HTA (Osteba)/Basque Foundation for Health Innovation and Research (BIOEF), Barakaldo, Spain.
Gaizka Benguria-ArrateBasque Office for HTA (Osteba)/Basque Foundation for Health Innovation and Research (BIOEF), Barakaldo, Spain.
Kelly Rocío Chacón-AcevedoTranslational Research Group, Global Institute for Clinical Excellence, Keralty SAS, Bogotá, Colombia.
María Paula Gutiérrez-SepulvedaTranslational Research Group, Global Institute for Clinical Excellence, Keralty SAS, Bogotá, Colombia.
Eduardo Low-PadillaTranslational Research Group, Global Institute for Clinical Excellence, Keralty SAS, Bogotá, Colombia.
Ilich Herbert De La Hoz-SieglerTranslational Research Group, Global Institute for Clinical Excellence, Keralty SAS, Bogotá, Colombia.
Claudia Isabel Guevara-PérezTranslational Research Group, Global Institute for Clinical Excellence, Keralty SAS, Bogotá, Colombia.
Ángel Del Pozo-PérezBiokeralty Research Institute AIE, Miñano, Spain.
Marta SuárezBiokeralty Research Institute AIE, Miñano, Spain.
Hans Peter DaubendkHealth Partners, Cologne, Germany.
Maximilian OtteInternational HealthTechScan (i-HTS), Cologne, Germany.
Iñaki Gutiérrez-IbarluzeaBasque Office for HTA (Osteba)/Basque Foundation for Health Innovation and Research (BIOEF), Barakaldo, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Early advice in the process of developing health technologies allows manufacturers to plan their production and transfer to health care systems more accurately. This review aims to describe frameworks used within HTA and their current use by HTA Agencies. Material and methods: We carried out a systematic literature review in Pubmed, Embase, Scopus, and WoS, including all references published in Spanish and English. This was last updated in March 2022. We extracted all available information regarding the organizations involved, services offered, types of technology, collaborators involved, fees, output and impact. Websites of several HTA organizations and Google were also searched in order to update and complete the information obtained from this generic search. Results: Five-hundred and forty one articles were identified and screened, of which 26 met the eligibility criteria and were selected. Seven of them were non-systematic reviews that described two or more HTA organizations. Ten studies were focused on the advice offered by individual organizations, and eight described the EMA and EUnetHTA parallel or joint advice. We found variations in the technology assessed, services offered, stage of development and costs for advisory services. Conclusions: Early and scientific advice would help manufacturers focus their product development on what is needed for the management of specific diseases. Most of the examples or services found refer to drugs as well as to some medical devices and diagnostics. A common definition of the type of advice that could be offered for different health technologies by HTA bodies to ascertain health care systems and manufacturers' needs, in addition to the timeline in which that advice needs to be given, would help HTA bodies provide the right support at the right time. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020219401, PROSPERO CRD42020219401.

Indexed as

Delivery of Health CareTechnology Assessment, BiomedicalCosts and Cost Analysisbiomedicalearly adviceearly dialoguescientific advicesystematic reviewtechnology assessment

Identifiers

PMID36276363
PMCPMC9583828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.